WO2008021394A2 - Formulations pharmaceutiques d'agonistes cannabinoïdes et procédé d'utilisation - Google Patents
Formulations pharmaceutiques d'agonistes cannabinoïdes et procédé d'utilisation Download PDFInfo
- Publication number
- WO2008021394A2 WO2008021394A2 PCT/US2007/018062 US2007018062W WO2008021394A2 WO 2008021394 A2 WO2008021394 A2 WO 2008021394A2 US 2007018062 W US2007018062 W US 2007018062W WO 2008021394 A2 WO2008021394 A2 WO 2008021394A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dosage form
- cannabinoid
- hours
- oral dosage
- agonist
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compositions pharmaceutiques d'agonistes cannabinoïdes et utilisation correspondante permettant de prévenir ou de réduire au minimum le risque d'abus de ce produit et/ou de toxicité de ce produit par manipulation illicite intentionnelle ou non intentionnelle. Également, procédé permettant de prévenir ou de réduire au minimum le risque d'abus de ce produit et/ou de toxicité de ce produit par manipulation illicite intentionnelle ou non intentionnelle.
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US83760706P | 2006-08-15 | 2006-08-15 | |
US83760606P | 2006-08-15 | 2006-08-15 | |
US60/837,607 | 2006-08-15 | ||
US60/837,606 | 2006-08-15 | ||
US84235906P | 2006-09-06 | 2006-09-06 | |
US60/842,359 | 2006-09-06 | ||
US84900606P | 2006-10-04 | 2006-10-04 | |
US60/849,006 | 2006-10-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008021394A2 true WO2008021394A2 (fr) | 2008-02-21 |
WO2008021394A3 WO2008021394A3 (fr) | 2008-12-31 |
Family
ID=39082712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/018062 WO2008021394A2 (fr) | 2006-08-15 | 2007-08-15 | Formulations pharmaceutiques d'agonistes cannabinoïdes et procédé d'utilisation |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008021394A2 (fr) |
Cited By (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011190259A (ja) * | 2010-03-11 | 2011-09-29 | Wyeth Llc | メチルナルトレキソンの経口製剤および親油性塩 |
WO2011141241A1 (fr) * | 2010-05-14 | 2011-11-17 | Ethypharm | Forme pharmaceutique orale alcoolo-resistante |
CN103338768A (zh) * | 2010-12-13 | 2013-10-02 | 托马斯·朱利叶斯·波洛迪 | 胃和结肠的配制剂及其制备和使用方法 |
WO2014022541A1 (fr) * | 2012-08-01 | 2014-02-06 | Acura Pharmaceuticals, Inc. | Stabilisation de systèmes de synthèse de la méthamphétamine en enceinte unique |
US20140220146A1 (en) * | 2008-07-07 | 2014-08-07 | Euro-Celtique S.A. | Use of opioid antagonists for treating urinary retention |
CN104010642A (zh) * | 2011-10-27 | 2014-08-27 | 萨利克斯药品有限公司 | 电解质泻药 |
US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
CN104940165A (zh) * | 2015-07-23 | 2015-09-30 | 北京康远制药有限公司 | 一种含有多库酯钠和丹蒽醌的胶囊剂及其制备方法 |
AU2013203559B2 (en) * | 2010-03-11 | 2015-12-03 | Wyeth Llc | Oral formulations and lipophilic salts of methylnaltrexone |
WO2016010771A1 (fr) * | 2014-07-17 | 2016-01-21 | Pharmaceutical Manufacturing Research Services, Inc. | Forme posologique remplie de liquide anti-abus à libération immédiate |
WO2016029215A1 (fr) * | 2014-08-22 | 2016-02-25 | Medipath, Inc. | Compositions et procédés d'enrobages en cannabinoïdes utilisés dans l'administration de médicaments |
WO2015153984A3 (fr) * | 2014-04-04 | 2016-03-03 | Pharmaquest International Center, LLC | Comprimés monolithiques à libération modifiée se désintégrant, contenant des granules à libération prolongée quadri-couches |
WO2016105498A1 (fr) | 2014-12-23 | 2016-06-30 | Synthetic Biologics, Inc. | Méthodes et compositions pour inhiber ou prévenir les effets néfastes des antibiotiques oraux |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
AU2016200133B2 (en) * | 2010-03-11 | 2017-09-07 | Wyeth Llc | Oral formulations and lipophilic salts of methylnaltrexone |
US9877925B2 (en) | 2010-05-14 | 2018-01-30 | Ethypharm | Alcohol-resistant oral pharmaceutical form |
US10159268B2 (en) | 2013-02-08 | 2018-12-25 | General Mills, Inc. | Reduced sodium food products |
US10166219B2 (en) | 2012-07-27 | 2019-01-01 | Redhill Bipharma Ltd. | Formulations and methods of manufacturing formulations for use in colonic evacuation |
US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US10195153B2 (en) | 2013-08-12 | 2019-02-05 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
CN109419665A (zh) * | 2017-08-25 | 2019-03-05 | 汉义生物科技(北京)有限公司 | 一种含有大麻提取物或大麻二酚的活性物快速渗透体系 |
US10376584B2 (en) | 2003-04-08 | 2019-08-13 | Progenics Pharmaceuticals, Inc. | Stable pharmaceutical formulations of methylnaltrexone |
WO2019198001A1 (fr) * | 2018-04-11 | 2019-10-17 | Ghs Patents Limited | Procede de fabrication d'un spheroide comprenant du cannabidiol |
US10512615B1 (en) | 2018-08-27 | 2019-12-24 | Axcess Global Sciences, Llc | Compositions and methods for delivering cannabidiol and ketone bodies |
US10561649B2 (en) | 2007-07-03 | 2020-02-18 | Sucampo Ag | Pharmaceutical combination of opioid and prostaglandin compound |
US20200061021A1 (en) * | 2018-08-27 | 2020-02-27 | Axcess Global Sciences, Llc | Compositions and methods for delivering tetrahydrocannabinol and ketone bodies |
WO2020046954A1 (fr) * | 2018-08-27 | 2020-03-05 | Axcess Global Sciences, Llc | Compositions et procédés pour administrer du tétrahydrocannabinol et des corps cétoniques |
US10583096B2 (en) | 2016-03-31 | 2020-03-10 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US10588876B2 (en) | 2017-11-22 | 2020-03-17 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US10596130B2 (en) | 2017-12-19 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
US10596128B2 (en) | 2017-12-19 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
US10596129B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US10596131B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US10603288B2 (en) | 2014-06-17 | 2020-03-31 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
WO2020086007A1 (fr) * | 2018-10-22 | 2020-04-30 | Oezel Oemer Faruk | Paquet pour une intervention rapide en cas d'infarctus du myocarde |
WO2020092451A1 (fr) * | 2018-10-29 | 2020-05-07 | Keto Patent Group, Inc. | Administration à l'homme de butyrate, de bêta-hydroxybutyrate, de cannabidiol et de composés apparentés |
US10709674B2 (en) | 2014-10-14 | 2020-07-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US10709671B2 (en) | 2015-06-17 | 2020-07-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US10729665B2 (en) | 2011-09-29 | 2020-08-04 | Gw Pharma Limited | Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
US10736861B2 (en) | 2016-03-11 | 2020-08-11 | Axcess Global Sciences, Llc | Mixed salt compositions for producing elevated and sustained ketosis |
US10765643B2 (en) | 2014-10-14 | 2020-09-08 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
US10918608B2 (en) | 2014-10-14 | 2021-02-16 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
US10925843B2 (en) | 2018-04-18 | 2021-02-23 | Axcess Global Sciences, Llc | Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate |
US10959958B2 (en) | 2014-10-20 | 2021-03-30 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
US10973792B2 (en) | 2019-02-13 | 2021-04-13 | Axcess Global Sciences, Llc | Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use |
US10973786B2 (en) | 2016-03-11 | 2021-04-13 | Axcess Global Sciences, Llc | R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions |
EP3808336A1 (fr) * | 2019-10-16 | 2021-04-21 | ADD Advanced Drug Delivery Technologies, Ltd. | Formulations à libération contrôlée des substances actives physiologiques très lipophiles |
CN112770726A (zh) * | 2018-07-18 | 2021-05-07 | 戈拉特有限责任公司 | 大麻素的缓释配方 |
US11033553B2 (en) | 2019-06-21 | 2021-06-15 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
US20210196772A1 (en) * | 2019-12-27 | 2021-07-01 | Grove Collaborative, Inc. | Confections for skin protection: compositions, methods for making, and applications thereof |
US11065227B2 (en) | 2016-08-25 | 2021-07-20 | GW Research Limited | Use of cannabinoids in the treatment of multiple myeloma |
US11103470B2 (en) | 2017-11-22 | 2021-08-31 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US11129802B2 (en) | 2018-08-27 | 2021-09-28 | Axcess Global Sciences, Llc | Compositions and methods for delivering cannabidiol and ketone bodies |
WO2021194910A1 (fr) * | 2020-03-22 | 2021-09-30 | Aardvark Therapeutics Inc. | Méthode de traitement du sras et de traitement ou de prévention du sdra |
US11147783B2 (en) | 2015-08-10 | 2021-10-19 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US11160795B2 (en) | 2020-02-27 | 2021-11-02 | GW Research Limited | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
US11185518B2 (en) | 2017-12-19 | 2021-11-30 | Axcess Global Sciences, Llc | S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer |
US11202769B2 (en) | 2017-11-22 | 2021-12-21 | Axcess Global Sciences, Llc | Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function |
US11229612B2 (en) | 2016-07-01 | 2022-01-25 | GW Research Limited | Parenteral formulations |
US11241403B2 (en) | 2016-03-11 | 2022-02-08 | Axcess Global Sciences, Llc | Beta-hydroxybutyrate mixed salt compositions and methods of use |
US11241401B2 (en) | 2020-02-06 | 2022-02-08 | Axcess Global Sciences, Llc | Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions |
US11291631B2 (en) | 2016-07-01 | 2022-04-05 | GW Research Limited | Oral cannabinoid formulations |
WO2022076470A1 (fr) * | 2020-10-06 | 2022-04-14 | Sorrento Therapeutics, Inc. | Formulation orale à libération rapide retardée de naltrexone ou de naloxone à faible dose utilisée pour traiter la fibromyalgie et le covid long |
US11419836B2 (en) | 2019-02-13 | 2022-08-23 | Axcess Global Sciences, Llc | Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions |
US11426362B2 (en) | 2017-02-17 | 2022-08-30 | GW Research Limited | Oral cannabinoid formulations |
US11679087B2 (en) | 2016-12-16 | 2023-06-20 | GW Research Limited | Use of cannabinoids in the treatment of Angelman syndrome |
US11793770B2 (en) | 2014-06-27 | 2023-10-24 | GW Research Limited | 7-OH-cannabidiol (7-OH-CBD) and/or 7-OH-cannabidivarin (7-OH-CBDV) for use in the treatment of epilepsy |
US11806324B2 (en) | 2018-04-18 | 2023-11-07 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies |
US11806319B2 (en) | 2018-01-03 | 2023-11-07 | GW Research Limited | Pharmaceutical composition comprising a cannabinoid |
US11944598B2 (en) | 2017-12-19 | 2024-04-02 | Axcess Global Sciences, Llc | Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer |
US11950616B2 (en) | 2019-06-21 | 2024-04-09 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
US11969411B2 (en) | 2016-04-19 | 2024-04-30 | Axcess Global Sciences, Llc | Administration of berberine metabolites |
US11969430B1 (en) | 2023-03-10 | 2024-04-30 | Axcess Global Sciences, Llc | Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110560270B (zh) * | 2019-09-19 | 2020-10-20 | 昆明理工大学 | 一种毒砂组合抑制剂及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030124185A1 (en) * | 2001-08-06 | 2003-07-03 | Benjamin Oshlack | Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent |
US20040214837A1 (en) * | 2003-04-23 | 2004-10-28 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
-
2007
- 2007-08-15 WO PCT/US2007/018062 patent/WO2008021394A2/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030124185A1 (en) * | 2001-08-06 | 2003-07-03 | Benjamin Oshlack | Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent |
US20040214837A1 (en) * | 2003-04-23 | 2004-10-28 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
Cited By (133)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10376584B2 (en) | 2003-04-08 | 2019-08-13 | Progenics Pharmaceuticals, Inc. | Stable pharmaceutical formulations of methylnaltrexone |
US10561649B2 (en) | 2007-07-03 | 2020-02-18 | Sucampo Ag | Pharmaceutical combination of opioid and prostaglandin compound |
US20140220146A1 (en) * | 2008-07-07 | 2014-08-07 | Euro-Celtique S.A. | Use of opioid antagonists for treating urinary retention |
US10376505B2 (en) | 2010-03-11 | 2019-08-13 | Wyeth, Llc | Oral formulations and lipophilic salts of methylnaltrexone |
JP2017206553A (ja) * | 2010-03-11 | 2017-11-24 | ワイス・エルエルシー | メチルナルトレキソンの経口製剤および親油性塩 |
EP3178472A1 (fr) * | 2010-03-11 | 2017-06-14 | Wyeth LLC | Formulations orales de la méthylnaltrexone |
US8524276B2 (en) | 2010-03-11 | 2013-09-03 | Wyeth, Llc | Oral formulations and lipophilic salts of methylnaltrexone |
US10307417B2 (en) | 2010-03-11 | 2019-06-04 | Wyeth, Llc | Oral formulations and lipophilic salts of methylnaltrexone |
JP2016029054A (ja) * | 2010-03-11 | 2016-03-03 | ワイス・エルエルシー | メチルナルトレキソンの経口製剤および親油性塩 |
CN107308125A (zh) * | 2010-03-11 | 2017-11-03 | 惠氏有限责任公司 | 甲基纳曲酮的口服制剂和亲脂盐 |
AU2016200133B2 (en) * | 2010-03-11 | 2017-09-07 | Wyeth Llc | Oral formulations and lipophilic salts of methylnaltrexone |
US8956651B2 (en) | 2010-03-11 | 2015-02-17 | Wyeth, Llc | Oral formulations and lipophilic salts of methylnal trexone |
JP2011190259A (ja) * | 2010-03-11 | 2011-09-29 | Wyeth Llc | メチルナルトレキソンの経口製剤および親油性塩 |
US9314461B2 (en) | 2010-03-11 | 2016-04-19 | Wyeth, Llc | Oral formulations and lipophilic salts of methylnaltrexone |
AU2011224275B2 (en) * | 2010-03-11 | 2015-10-01 | Wyeth Llc | Oral formulations and lipophilic salts of methylnaltrexone |
AU2013203559B2 (en) * | 2010-03-11 | 2015-12-03 | Wyeth Llc | Oral formulations and lipophilic salts of methylnaltrexone |
US10507206B2 (en) | 2010-03-11 | 2019-12-17 | Wyeth, Llc | Oral formulations and lipophilic salts of methylnaltrexone |
EP2371357A1 (fr) * | 2010-03-11 | 2011-10-05 | Wyeth LLC | Formulations orales et sels lipophiles de la méthylnaltrexone |
AU2011252310B2 (en) * | 2010-05-14 | 2016-01-07 | Ethypharm | Alcohol-resistant oral pharmaceutical form |
FR2959935A1 (fr) * | 2010-05-14 | 2011-11-18 | Ethypharm Sa | Forme pharmaceutique orale alcoolo-resistante |
US9877925B2 (en) | 2010-05-14 | 2018-01-30 | Ethypharm | Alcohol-resistant oral pharmaceutical form |
WO2011141241A1 (fr) * | 2010-05-14 | 2011-11-17 | Ethypharm | Forme pharmaceutique orale alcoolo-resistante |
JP2016106078A (ja) * | 2010-05-14 | 2016-06-16 | エティファルムEthypharm | アルコール耐性経口医薬形態 |
CN102970983A (zh) * | 2010-05-14 | 2013-03-13 | 爱的发制药集团 | 耐受酒精的口服药物制剂 |
JP2013530138A (ja) * | 2010-05-14 | 2013-07-25 | エティファルム | アルコール耐性経口医薬形態 |
CN103338768A (zh) * | 2010-12-13 | 2013-10-02 | 托马斯·朱利叶斯·波洛迪 | 胃和结肠的配制剂及其制备和使用方法 |
CN103338768B (zh) * | 2010-12-13 | 2019-04-19 | 萨利克斯药品有限公司 | 胃和结肠的配制剂及其制备和使用方法 |
US10092573B2 (en) | 2010-12-13 | 2018-10-09 | Salix Pharmaceuticals, Inc. | Gastric and colonic formulations and methods for making and using them |
US11318109B2 (en) | 2011-09-29 | 2022-05-03 | Gw Pharma Limited | Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
US10729665B2 (en) | 2011-09-29 | 2020-08-04 | Gw Pharma Limited | Pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
CN104010642A (zh) * | 2011-10-27 | 2014-08-27 | 萨利克斯药品有限公司 | 电解质泻药 |
US10166219B2 (en) | 2012-07-27 | 2019-01-01 | Redhill Bipharma Ltd. | Formulations and methods of manufacturing formulations for use in colonic evacuation |
WO2014022541A1 (fr) * | 2012-08-01 | 2014-02-06 | Acura Pharmaceuticals, Inc. | Stabilisation de systèmes de synthèse de la méthamphétamine en enceinte unique |
US11540539B2 (en) | 2013-02-08 | 2023-01-03 | General Mills, Inc. | Reduced sodium food products |
US10159268B2 (en) | 2013-02-08 | 2018-12-25 | General Mills, Inc. | Reduced sodium food products |
US10195153B2 (en) | 2013-08-12 | 2019-02-05 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
US10639281B2 (en) | 2013-08-12 | 2020-05-05 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
US10792254B2 (en) | 2013-12-17 | 2020-10-06 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
WO2015153984A3 (fr) * | 2014-04-04 | 2016-03-03 | Pharmaquest International Center, LLC | Comprimés monolithiques à libération modifiée se désintégrant, contenant des granules à libération prolongée quadri-couches |
US11813361B2 (en) | 2014-04-04 | 2023-11-14 | Pharmaquest International Center, Llp | Disintegrating monolithic modified release tablets containing quadri-layer extended release granules |
US11766411B2 (en) | 2014-06-17 | 2023-09-26 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US10603288B2 (en) | 2014-06-17 | 2020-03-31 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US11963937B2 (en) | 2014-06-17 | 2024-04-23 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US11154516B2 (en) | 2014-06-17 | 2021-10-26 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US11311498B2 (en) | 2014-06-17 | 2022-04-26 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US11701330B2 (en) | 2014-06-17 | 2023-07-18 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US11793770B2 (en) | 2014-06-27 | 2023-10-24 | GW Research Limited | 7-OH-cannabidiol (7-OH-CBD) and/or 7-OH-cannabidivarin (7-OH-CBDV) for use in the treatment of epilepsy |
WO2016010771A1 (fr) * | 2014-07-17 | 2016-01-21 | Pharmaceutical Manufacturing Research Services, Inc. | Forme posologique remplie de liquide anti-abus à libération immédiate |
US9707184B2 (en) | 2014-07-17 | 2017-07-18 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
AU2015290098B2 (en) * | 2014-07-17 | 2018-11-01 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
WO2016029215A1 (fr) * | 2014-08-22 | 2016-02-25 | Medipath, Inc. | Compositions et procédés d'enrobages en cannabinoïdes utilisés dans l'administration de médicaments |
US10092559B2 (en) | 2014-09-12 | 2018-10-09 | Recro Gainesville Llc | Abuse resistant pharmaceutical compositions |
US9452163B2 (en) | 2014-09-12 | 2016-09-27 | Recro Gainesville Llc | Abuse resistant pharmaceutical compositions |
US9486451B2 (en) | 2014-09-12 | 2016-11-08 | Recro Gainesville Llc | Abuse resistant pharmaceutical compositions |
US10960000B2 (en) | 2014-09-12 | 2021-03-30 | Recro Gainesville Llc | Abuse resistant pharmaceutical compositions |
US9713611B2 (en) | 2014-09-12 | 2017-07-25 | Recro Gainesville, LLC | Abuse resistant pharmaceutical compositions |
US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
US10709673B2 (en) | 2014-10-14 | 2020-07-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US10849860B2 (en) | 2014-10-14 | 2020-12-01 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US11065209B2 (en) | 2014-10-14 | 2021-07-20 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
US11446258B2 (en) | 2014-10-14 | 2022-09-20 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US11154517B2 (en) | 2014-10-14 | 2021-10-26 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US10709674B2 (en) | 2014-10-14 | 2020-07-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US10966939B2 (en) | 2014-10-14 | 2021-04-06 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US11096905B2 (en) | 2014-10-14 | 2021-08-24 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US11633369B2 (en) | 2014-10-14 | 2023-04-25 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US10918608B2 (en) | 2014-10-14 | 2021-02-16 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
US10765643B2 (en) | 2014-10-14 | 2020-09-08 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
US11400055B2 (en) | 2014-10-14 | 2022-08-02 | GW Research Limited | Use of cannabidiol in the treatment of epilepsy |
US10959958B2 (en) | 2014-10-20 | 2021-03-30 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
US11944669B2 (en) | 2014-12-23 | 2024-04-02 | Theriva Biologics, Inc. | Method and compositions for inhibiting or preventing adverse effects of oral antibiotics |
EP3236993A4 (fr) * | 2014-12-23 | 2018-08-08 | Synthetic Biologics Inc. | Méthodes et compositions pour inhiber ou prévenir les effets néfastes des antibiotiques oraux |
WO2016105498A1 (fr) | 2014-12-23 | 2016-06-30 | Synthetic Biologics, Inc. | Méthodes et compositions pour inhiber ou prévenir les effets néfastes des antibiotiques oraux |
US11596674B2 (en) | 2014-12-23 | 2023-03-07 | Synthetic Biologies, Inc. | Method and compositions for inhibiting or preventing adverse effects of oral antibiotics |
US10709671B2 (en) | 2015-06-17 | 2020-07-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US11357741B2 (en) | 2015-06-17 | 2022-06-14 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
CN104940165A (zh) * | 2015-07-23 | 2015-09-30 | 北京康远制药有限公司 | 一种含有多库酯钠和丹蒽醌的胶囊剂及其制备方法 |
US11147783B2 (en) | 2015-08-10 | 2021-10-19 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US11684598B2 (en) | 2015-08-10 | 2023-06-27 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US10736861B2 (en) | 2016-03-11 | 2020-08-11 | Axcess Global Sciences, Llc | Mixed salt compositions for producing elevated and sustained ketosis |
US11896565B2 (en) | 2016-03-11 | 2024-02-13 | Axcess Global Sciences, Llc | Beta-hydroxybutyrate mixed salt compositions and methods of use |
US11020362B2 (en) | 2016-03-11 | 2021-06-01 | Axcess Global Sciences, Llc | Beta-hydroxybutyrate mixed salt compositions and methods of use |
US10973786B2 (en) | 2016-03-11 | 2021-04-13 | Axcess Global Sciences, Llc | R-beta-hydroxybutyrate, S-beta-hydroxybutyrate, and RS-beta-hydroxybutyrate mixed salt compositions |
US11241403B2 (en) | 2016-03-11 | 2022-02-08 | Axcess Global Sciences, Llc | Beta-hydroxybutyrate mixed salt compositions and methods of use |
US10583096B2 (en) | 2016-03-31 | 2020-03-10 | GW Research Limited | Use of cannabinoids in the treatment of epilepsy |
US11969411B2 (en) | 2016-04-19 | 2024-04-30 | Axcess Global Sciences, Llc | Administration of berberine metabolites |
US11229612B2 (en) | 2016-07-01 | 2022-01-25 | GW Research Limited | Parenteral formulations |
US11291631B2 (en) | 2016-07-01 | 2022-04-05 | GW Research Limited | Oral cannabinoid formulations |
US11065227B2 (en) | 2016-08-25 | 2021-07-20 | GW Research Limited | Use of cannabinoids in the treatment of multiple myeloma |
US11679087B2 (en) | 2016-12-16 | 2023-06-20 | GW Research Limited | Use of cannabinoids in the treatment of Angelman syndrome |
US11426362B2 (en) | 2017-02-17 | 2022-08-30 | GW Research Limited | Oral cannabinoid formulations |
CN109419665A (zh) * | 2017-08-25 | 2019-03-05 | 汉义生物科技(北京)有限公司 | 一种含有大麻提取物或大麻二酚的活性物快速渗透体系 |
US10596129B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US11690817B2 (en) | 2017-11-22 | 2023-07-04 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US11786499B2 (en) | 2017-11-22 | 2023-10-17 | Axcess Global Sciences, Llc | Ketone body esters of S-beta-hydroxybutyrate and/or S-1,3-butanediol for modifying metabolic function |
US10588876B2 (en) | 2017-11-22 | 2020-03-17 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US11202769B2 (en) | 2017-11-22 | 2021-12-21 | Axcess Global Sciences, Llc | Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function |
US11103470B2 (en) | 2017-11-22 | 2021-08-31 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US10596131B2 (en) | 2017-11-22 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use |
US11185518B2 (en) | 2017-12-19 | 2021-11-30 | Axcess Global Sciences, Llc | S-beta-hydroxybutyrate compounds and compositions enriched with S-enantiomer |
US10596130B2 (en) | 2017-12-19 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
US10596128B2 (en) | 2017-12-19 | 2020-03-24 | Axcess Global Sciences, Llc | Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the S-enantiomer and methods of use |
US11944598B2 (en) | 2017-12-19 | 2024-04-02 | Axcess Global Sciences, Llc | Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer |
US11806319B2 (en) | 2018-01-03 | 2023-11-07 | GW Research Limited | Pharmaceutical composition comprising a cannabinoid |
FR3080278A1 (fr) * | 2018-04-11 | 2019-10-25 | Ghs Patents Limited | Procede de fabrication d'un spheroide de cannabidiol |
WO2019198001A1 (fr) * | 2018-04-11 | 2019-10-17 | Ghs Patents Limited | Procede de fabrication d'un spheroide comprenant du cannabidiol |
US10925843B2 (en) | 2018-04-18 | 2021-02-23 | Axcess Global Sciences, Llc | Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate |
US11793778B2 (en) | 2018-04-18 | 2023-10-24 | Axcess Global Sciences, Llc | Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate |
US11806324B2 (en) | 2018-04-18 | 2023-11-07 | Axcess Global Sciences, Llc | Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies |
CN112770726A (zh) * | 2018-07-18 | 2021-05-07 | 戈拉特有限责任公司 | 大麻素的缓释配方 |
US10980772B2 (en) * | 2018-08-27 | 2021-04-20 | Axcess Global Sciences, Llc | Compositions and methods for delivering tetrahydrocannabinol and ketone bodies |
WO2020046954A1 (fr) * | 2018-08-27 | 2020-03-05 | Axcess Global Sciences, Llc | Compositions et procédés pour administrer du tétrahydrocannabinol et des corps cétoniques |
US10512615B1 (en) | 2018-08-27 | 2019-12-24 | Axcess Global Sciences, Llc | Compositions and methods for delivering cannabidiol and ketone bodies |
US20200061021A1 (en) * | 2018-08-27 | 2020-02-27 | Axcess Global Sciences, Llc | Compositions and methods for delivering tetrahydrocannabinol and ketone bodies |
US11129802B2 (en) | 2018-08-27 | 2021-09-28 | Axcess Global Sciences, Llc | Compositions and methods for delivering cannabidiol and ketone bodies |
WO2020086007A1 (fr) * | 2018-10-22 | 2020-04-30 | Oezel Oemer Faruk | Paquet pour une intervention rapide en cas d'infarctus du myocarde |
WO2020092451A1 (fr) * | 2018-10-29 | 2020-05-07 | Keto Patent Group, Inc. | Administration à l'homme de butyrate, de bêta-hydroxybutyrate, de cannabidiol et de composés apparentés |
US10973792B2 (en) | 2019-02-13 | 2021-04-13 | Axcess Global Sciences, Llc | Racemic beta-hydroxybutyrate mixed salt-acid compositions and methods of use |
US11419836B2 (en) | 2019-02-13 | 2022-08-23 | Axcess Global Sciences, Llc | Racemic and near racemic beta-hydroxybutyrate mixed salt-acid compositions |
US11033553B2 (en) | 2019-06-21 | 2021-06-15 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
US11950616B2 (en) | 2019-06-21 | 2024-04-09 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
WO2021074399A1 (fr) * | 2019-10-16 | 2021-04-22 | Add Advanced Drug Delivery Technologies Ltd. | Formulations à libération contrôlée de substances physiologiquement actives hautement lipophiles |
EP3808336A1 (fr) * | 2019-10-16 | 2021-04-21 | ADD Advanced Drug Delivery Technologies, Ltd. | Formulations à libération contrôlée des substances actives physiologiques très lipophiles |
US20210196772A1 (en) * | 2019-12-27 | 2021-07-01 | Grove Collaborative, Inc. | Confections for skin protection: compositions, methods for making, and applications thereof |
US11241401B2 (en) | 2020-02-06 | 2022-02-08 | Axcess Global Sciences, Llc | Enantiomerically pure r-beta-hydroxybutyrate mixed salt-acid compositions |
US11160795B2 (en) | 2020-02-27 | 2021-11-02 | GW Research Limited | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
US11406623B2 (en) | 2020-02-27 | 2022-08-09 | GW Research Limited | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
WO2021194910A1 (fr) * | 2020-03-22 | 2021-09-30 | Aardvark Therapeutics Inc. | Méthode de traitement du sras et de traitement ou de prévention du sdra |
WO2022076470A1 (fr) * | 2020-10-06 | 2022-04-14 | Sorrento Therapeutics, Inc. | Formulation orale à libération rapide retardée de naltrexone ou de naloxone à faible dose utilisée pour traiter la fibromyalgie et le covid long |
US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
US11969430B1 (en) | 2023-03-10 | 2024-04-30 | Axcess Global Sciences, Llc | Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance |
Also Published As
Publication number | Publication date |
---|---|
WO2008021394A3 (fr) | 2008-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008021394A2 (fr) | Formulations pharmaceutiques d'agonistes cannabinoïdes et procédé d'utilisation | |
WO2008024490A2 (fr) | Formulations pharmaceutiques à usage oral de cannabinoïdes dissuadant les abus et leur procédé d'utilisation | |
WO2008027442A2 (fr) | Formulations pharmaceutiques orales anti-abus à base d'opioïdes et procédé d'utilisation | |
US20110097395A1 (en) | Oral Pharmaceutical Compositions of Buprenorphine and Method of Use | |
US9125833B2 (en) | Multimodal abuse resistant and extended release opioid formulations | |
EP2448406B1 (fr) | Compositions pharmaceutiques orales à libération prolongée de 3-hydroxy-n-méthylmorphinane et procédé d'utilisation | |
JP4504013B2 (ja) | 放出可能な及び封鎖されたアンタゴニストを有するオピオイドアゴニスト製剤 | |
JP5566102B2 (ja) | 医薬組成物 | |
ES2415407T3 (es) | Formulaciones orales de agonistas opioides resistentes a manipulaciones indebidas | |
WO2008033351A2 (fr) | Formulations multimode de libération prolongée et résistantes à l'abus | |
HUE028041T2 (en) | For opioid administration of anti-manipulation products | |
US20100210732A1 (en) | Methods of Preventing the Serotonin Syndrome and Compositions for Use Therefor | |
CA2709905A1 (fr) | Composition d'oxycodone a l'epreuve d'un usage abusif | |
US9364430B2 (en) | Compositions of (-)-17-(cyclobutylmethyl)morphinan-3,14-diol | |
WO2010104494A1 (fr) | Compositions pharmaceutiques à libération modifiée de buprénorphine | |
AU2015200313B2 (en) | Pharmaceutical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07811348 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
NENP | Non-entry into the national phase in: |
Ref country code: RU |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07811348 Country of ref document: EP Kind code of ref document: A2 |